Loading stock data…
INNV
$8.32+0.17 (+2.09%)
After Hours$8.32+0.00 (+0.00%)· Last close May 1
InnovAge Holding Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InnovAge Holding Corp. in the Healthcare sector is trading at $8.32. The stock is currently 22% below its 52-week high of $10.69, remaining 40.8% above its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why INNV maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.32
Potential Downside
89.8%
Whystock Fair Value$0.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Hold
Mean target$7.00-15.9%
Range$7.00 – $7.00
Fundamentals
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. It manages its business through Program of All-Inclusive Care for the El...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
153.00
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.80%
Volume
Today's trading volume
117,719
Recent News
Humana Bets on Pharmacists to Lift Chronic Care Outcomes
HUM taps pharmacists via a value-based program in Ohio to boost hypertension and diabetes outcomes while aiming to curb costs and improve care access.
How The InnovAge Holding (INNV) Story Is Evolving After JPMorgan’s Updated US$7 Target
JPMorgan has lifted its price target on InnovAge Holding to US$7 from US$5, putting a new marker on where its model says the shares could reasonably trade. The firm still keeps an Underweight rating; the higher target reflects refreshed assumptions in its framework rather than a shift in stance. As you read on, you will see how this updated target fits into the broader analyst narrative and what to watch as that story develops. Stay updated as the Fair Value for InnovAge Holding shifts by...
Why Teladoc Deserves Patience Now: Too Early to Buy, Too Risky to Sell
TDOC trades at a discount as Teladoc expands AI-driven care, cuts costs, and eyes better profitability, but BetterHelp weakness and rising competition cloud outlook.
CNC Combines Its North Carolina Units to Expand Statewide Footprint
Centene merges its North Carolina units into Carolina Complete Health and aims to streamline Medicaid operations while serving over 980,000 members statewide.
Take the Zacks Approach to Beat the Markets: Stride, InnovAge, PepsiCo in Focus
LRN's surge, INNV's upgrade-driven rally and PEP's steady gains showcase how Zacks strategies are outperforming despite ongoing market volatility.